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Rationale and design of PREvalence 
of DyspneA in patients treated with 
TicagrelOR (PREDATOR) program
AbsTRAcT
Background: Ticagrelor, a reversible P2Y12 inhibitor, is a mainstay of antiplatelet strategy in patients with 
acute coronary syndrome (ACS). However, a large number of ticagrelor-induced dyspnea decrease patients’ 
adherence and reduce an overall efficacy of the therapy. 
Design: The PREDATOR program consists of phase III and IV, multicenter, randomized, double-blind, 
placebo-controlled clinical trials and preceding pilot studies that assesses the prevalence and treatment 
of ticagrelor-induced dyspnea in coronary artery disease (CAD) and ACS patients. The PREDATOR LD 
is designed to evaluate the occurrence of dyspnea after 180 mg ticagrelor loading dose, and relief of 
dyspnea by theophylline administration in low-to-high risk acute coronary syndromes without ST-segment 
elevation (NSTE-ACS) and stable CAD designated to undergo invasive treatment. The PREDATOR MD is 
a cross-over trial in stable CAD patients 1 year after percutaneous coronary intervention for ACS. Enrolled 
patients will be randomized to one of four antiplatelet treatment regimens (ticagrelor 2x90 mg, ticagrelor 
2x60 mg, ticagrelor 2x45 mg or clopidogrel 75 mg [morning]+placebo [evening]) or placebo and will be 
assessed for dyspnea at the day 7, then undergo a switch of treatment and reassessment at day 14. The 
sample size will be estimated based on preceding pilot studies.
Discussion: The PREDATOR LD is expected to prospectively assess dyspnea rate with a loading dose 
of ticagrelor, and analyze a potential of theophylline to elevate symptoms of ticagrelor-induced dyspnea, 
while the PREDATOR MD will prospectively assess dyspnea and adverse events rate with a maintenance 
dose of P2Y12 inhibitors prospectively assess. All evaluations will be conducted using standardized 
metrics for dyspnea quantification.
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Introduction
Antiplatelet therapy with P2Y12 inhibitors is a main-
stay strategy for the management of acute coronary syn-
drome (ACS) patients. Ticagrelor, novel and reversible 
P2Y12 inhibitor, is recommended as a class I therapy for 
12 months after an ACS event by the European Society 
of Cardiology and the American College of Cardiolo-
gy/American Heart Association guideline committees 
[1–3]. The optimal antiplatelet effect prevents from 
thrombotic complications, including devastating in con-
sequences stent thrombosis that drives cardiovascular 
mortality in the early stage post percutaneous coronary 
intervention (PCI) [4–7]. The potency of antithrombot-
ic strategy with novel P2Y12 inhibitor, ticargelor, as 
compared to its irreversible counterpart clopidogrel, is 
well established [8–10]. In large randomized controlled 
trial (RCT) ticagrelor (90 mg or 60 mg, twice daily) in 
combination with aspirin significantly reduced the risk 
of cardiovascular death, myocardial infarction (MI), or 
stroke as compared with clopidogrel in patients who 
had prior MI 1–3 years earlier [11]. Bleeding and respi-
ratory adverse events, however, were more frequently 
observed with ticagrelor use. 
One of the reasons of ineffectiveness of antiplatelet 
therapy originates from low adherence and discontin-
uation of the therapy due to adverse events [12–17]. 
Dyspnea is a relatively frequent adverse event ob-
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served during ticagrelor therapy, and while it is usually 
reported as “mild” or “moderate” in intensity among 
patients experiencing it, it remains an overt reason 
for discontinuation of the assigned treatment [18]. In 
the secondary analysis of the PEGASUS-TIMI 54 Trial 
the rate of discontinuation due to an adverse event 
was the highest in the treatment arm receiving 90 mg 
of ticagrelor (19%), followed by the treatment arm re-
ceiving 60 mg of ticagrelor (16%), both of which were 
significantly higher than that in the placebo arm (9%), 
with the differences most marked within the first year 
from randomization [19]. A dose-dependent relative 
increase of both dyspnea and dyspnea requiring dis-
continuation was present, however, the discontinuation 
rate resulting from dyspnea among those subjects, who 
reported dyspnea, was 5-flod higher than observed in 
the PLATO trial. Interestingly, discontinuation due to 
dyspnea (6.2% ticagrelor 90 mg bid vs 4.3% ticagrelor 
60 mg bid vs 0.7% placebo) had the same prevalence 
as the disocntinuation due to bleeding (6.5% ticagrelor 
90 mg bid vs 5.1% ticagrelor 60 mg bid vs 1.2% pla-
cebo). The increased risk of bleeding is on the other 
side of spectrum of thrombotic milieu and is inevitable 
in successful antithrombotic management; dyspnea, 
however, remains an adverse event with a high potential 
of prevention [14]. Ticagrelor-induced dyspnea exerts 
generally no effort on the patient’s activities of daily life 
and can be resolved quickly, as it does not influence 
the patient’s cardiac nor pulmonary function. Taking 
together not sufficient awareness of the recognition and 
management of ticagrelor-related dyspnea, especially 
among elderly ACS patients treated with several drugs, 
there exists a global underestimation and mismanage-
ment of this adverse event [20]. For a proper manage-
ment of patients complaining of dyspnea when taking 
ticagrelor, all clinically plausible causes of dyspnea 
must be considered before attributing it to medication 
itself [21]. Episodes of dyspnea tend to occur during 
first days after the initiation of the therapy [18]. Dyspnea 
may have devastating effects when leading to treatment 
discontinuation, especially in the case of frail population 
as ACS patients. In the first multicenter observational 
prospective study to investigate rate of ticagrelor-re-
lated dyspnea and its impact on daily life in patients in 
their first month post PCI, ticagrelor was withdrawn in 
16.7% patients during the 1st month of follow-up, with 
ticagrelor-related dyspnea at the rate of 55.6% of all 
withdrawal reasons [22]. To provide further optimization 
of the antiplatelet strategies it is mandatory to avoid 
discontinuation due to a preventable adverse event. 
A number of potential mechanisms could cause 
ticagrelor-induced dyspnea. It has been hypothesized 
that the sensation of dyspnea is related to reversibility of 
the P2Y12 inhibiting agent origins from increased levels 
of adenosine, which cellural reuptake is impaired [23]. 
Pulmonary vagal C fibres are stimulated by increased 
adenosine levels through the A1R and A2AR receptors 
on vagal sensory C fibers, which mediate the sensa-
tion of dyspnea. The increase in serum adenosine is 
higher with reversible (i.e. ticagrelor) rather than irre-
versible P2Y12 inhibitors (clopidogrel) [24]. Therefore, 
potential treatment options for ticagrelor-associated 
dyspnea may include adenosine antagonism, such 
as aminophylline or theophylline. The cases of suc-
cessful reversal of ticagrelor-induced dyspnea have 
been described in literature [25]. Their role is still 
not yet fully addressed in a large clinical study. In 
a promising randomized trial TROCADERO (TRial Of 
Caffeine to Alleviate DyspnEa Related to ticagrelOr) 
the primary objective was to assess the efficacy of 
caffeine in reducing symptoms of ticagrelor-induced 
dyspnea, measured by the visual analog scale area 
under the curve (VAS AUC), in patients after an ACS 
[26]. However, out of 514 subjects who participated 
in the questionnaire survey, only a small number of 
patients experienced dyspnea that required an inter-
vention and were randomized to one of the strategies: 
13 to caffeine, and 10 to placebo. In this context, dys-
pnea and treatment to evelate its symptoms were not 
prospectively assessed in a large study with a use of 
standardized tool, thus, its prevalence and severity is 
not well established.
In the PREDATOR program, we aim for the first time 
to 1) prospectively assess dyspnea rate with a loading 
dose of reversible P2Y12 inhibitor, ticagrelor, 2) analyze 
a potential of theophylline to elevate symptoms of tica-
grelor-induced dyspnea, 3) prospectively assess dys-
pnea and adverse events rate with a maintenance dose 
of P2Y12 inhibitors. All evaluations will be conducted 
using standardized metrics for dyspnea quantification.
Methods
Program design and objectives
The PREvalence of DyspneA in patients treated 
with TicagrelOR (PREDATOR) is an international, mul-
ticenter program consisting of two trials preceded by 
pilot studies (Figure 1). The inclusion and exclusion 
criteria for both PREDATOR Loading Dose (LD) Study 
and PREDATOR Maintenance Dose (MD) Study are 
presented in Table 1. The same criteria will apply to 
the pilot studies. The main objective of the program 
is to prospectively and quantitatively assess, with the 
use of a standardized score, prevalence of dyspnea 
with ticargelor and a potential of theophylline ad-
ministration on dyspnea cessation among ACS and 
stable CAD patients. The study will be conducted in 
accordance with the principles contained in the Dec-
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Figure 1. Schematic design of the PREDATOR program
Table 1. Inclusion and exclusion criteria of PREDATOR LD Study and PREDATOR MD Study
PREDATOR LD Study PREDATOR MD Study
Inclusion 
criteria
• diagnosis of low, intermediate or high risk NSTE-ACS 
designated to invasive treatment or diagnosis of stable 
coronary disease designated to invasive treatment
• diagnosis of stable coronary disease 1 year after PCI 
for acute coronary syndrome with known anatomy of 
coronary arteries designated to invasive treatment
• male or non-pregnant female
• age > 18 years old
• provision of informed consent for angiography and PCI
• provision of written informed consent to participate in the study
Exclusion 
criteria
• diagnosis of STEMI
• diagnosis of very high risk NSTE-ACS designated to 
immediate invasive treatment
• dyspnea present at screening
• contraindications for ticagrelor or theophylline
• second or third degree atrioventricular block during 
screening for eligibility
• diagnosis of acute coronary syndrome
• PCI with coronary stenting during the last 12 months
• chronic dyspnea present at screening (e.g. due to 
severe COPD)
• contraindications for ticagrelor, prasugrel, clopidogrel
• history of second or third degree atrioventricular block 
without implanted pacemaker
• treatment with ticagrelor or theophylline within 14 days before the study enrolment
• current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin
• active bleeding
• history of intracranial haemorrhage
• recent gastrointestinal bleeding (within 30 days)
• history of coagulation disorders
• history of moderate or severe hepatic impairment
• history of major surgery or severe trauma (within 3 months)
• patient required dialysis
• manifest infection or inflammatory state
• respiratory failure
• current therapy with strong CYP3A inhibitors or strong CYP3A inducers
laration of Helsinki, and every study site will receive 
an approval from the Local Ethics Committee. Each 
patient will provide a written informed consent to 
participate in the study.
Statistical design and analysis
Since the rate of dyspnea with ticagrelor use varies 
in definitions and rates across previously published 
literature, we decided to perform preceding pilot studies 
to estimate the sample size. 
PREDATOR LD
The PREDATOR LD is a double-blind, placebo-con-
trolled, randomized trial in low-to-high risk acute 
coronary syndromes without ST-segment elevation 
(NSTE-ACS) and stable coronary disease designated 
to undergo invasive treatment. The primary objective 
of the study is to evaluate the occurrence of dyspnea 
after 180 mg ticagrelor loading dose, with following 
secondary objective of assessing relief of dyspnea 
by theophylline administration. Patients will undergo 
two stages of randomization — first randomization to 
180 mg ticagrelor LD vs. placebo followed by a switch 
of therapy after 2 hours in patients without dyspnea, 
and second randomization to theophylline p.o. (load-
ing dose 5 mg/kg, maintenance dose 100 mg tid) 
vs. placebo p.o. of only patients with dyspnea in 1st 
randomization stage (Figure 2). The study follow-up will 
be stratified to three durations, driven by randomization: 
1) 1st follow-up, within 2 hours after first randomization 
(patients with dyspnea directly undergo second ran-
domization, while patients without dyspnea by the end 
of follow-up have the allocated therapy switched), 2) 2nd 
follow-up, within 2 hours after the 1st follow-up, up to 
4 hours after first randomization (patients with dyspnea 
undergo second randomization, while patients without 
dyspnea undergo coronary angiography/PCI), 3) 3rd 
follow-up, within 1 hour after second randomization, 
and up to 5 hours after first randomization (all patients 
undergo coronary angiography/PCI, while for patients 
in whom dyspnea have occurred at first follow-up period 
the study treatment will be unblinded after termination 
of the protocol and before PCI; patients in placebo arm 
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Table 2. Modified Borg Dyspnoea Scale
Rate Symptoms
0 Nothing at all
0.5 Very, very slight (just noticeable)
1 Very slight
2 Slight
3 Moderate
4 Somewhat severe
5 Severe
6
7 Very severe
8
9 Very, very severe (almost maximal)
10 Maximal
will unblindly receive ticagrelor LD). Dyspnea, as well as 
the relief from it, will be quantified with the Modified Borg 
Dyspnoea Score (Table 2). The exact number of study 
population will be determined based on the PREDATOR 
LD pilot study including 200 patients. 
PREDATOR MD
The PREDATOR MD is a double-blind, placebo-con-
trolled, cross-over, randomized trial conducted in stable 
coronary artery disease (CAD) patients 1 year after PCI 
for ACS. Enrolled patients will be randomized to one of 
four antiplatelet treatment regimens (ticagrelor 2x90 mg 
or ticagrelor 2x60 mg or ticagrelor 2x45 mg or clopido-
grel 75 mg [morning] + placebo [evening]) or placebo 
(1:1:1:1:1 ratio), and will be assessed for dyspnea at 
the day 7 of the allocated therapy. On the same day all 
patients will undergo a switch of treatment and will be 
reassessed for dyspnea at day 14. The primary objective 
of the study is to evaluate the occurrence of dyspnea 
with different maintenance dose of antiplatelet treatment 
regimens. Dyspnea will be quantified with the Modified 
Borg Dyspnoea Score. The secondary endpoints of this 
study, evaluating the safety of P2Y12 inhibiting therapy, 
include major bleedings according to the Thrombolysis 
In Myocardial Infarction (TIMI) criteria, minor bleedings 
according to TIMI criteria, clinically relevant bradycardia, 
level of serum uric acid, neutrophil count, overall prema-
ture discontinuation of the study drug and discontinua-
tion of the study drug due to dyspnoe. Discontinuation 
is defined as study drug cessation following medical 
contact. The exact number of study population will be 
determined based on the PREDATOR MD pilot study 
including 400 patients.
study organization
The executive committee is responsible for the 
overall design, conduct, and supervision of the study, 
Figure 2. PREDATOR LT Study design
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Figure 3. PREDATOR MD Study design
including the development of any protocol amend-
ments. The independent academic statistician will 
perform or confirm all statistical analyses of the final 
data. A National Leaders Committee, composed of 
lead investigators from each participating country, 
works in tandem with the Executive Committee. The 
executive committee is composed of representatives 
from the Collegium Medicum of Nicolaus Copernicus 
University (Bydgoszcz, Poland), and other collaborat-
ing centers. A clinical events committee reviews and 
adjudicates each suspected clinical end point event in 
a blinded fashion. 
conclusions
The PREDATOR program includes phase III and IV, 
multicenter, randomized, double-blind, placebo-controlled 
clinical trials that assesses the prevalence and treatment of 
ticagrelor-induced dyspnea in CAD/ACS patients. Those 
trials will provide important information regarding the 
impact of ticagrelor loading and maintenance dose on 
the occurrence and severity of dyspnea, prospectively 
assessed by a standardized score. A disclosure of such 
information could provide medical practitioners with more 
effective tools preventing from consequences of therapy 
discontinuation due to mild adverse events.
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